ReviewCurrent neurology and neuroscience reports2025
Systemic Comorbidities as Modifiers of Outcome After Endovascular Thrombectomy for Acute Ischemic Stroke.
Review in Current neurology and neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpretable machine learning-based prediction of 90-day mortality after endovascular treatment in acute large vessel occlusion stroke.Frontiers in neurology · 2026Article
- Anesthesia Considerations in Older Adults Undergoing Emergency Mechanical Thrombectomy for Acute Ischaemic Stroke.Drugs & aging · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo evaluate the impact of systemic comorbidities on outcomes following endovascular thrombectomy (EVT) for acute ischemic stroke. RECENT
findingsAlthough EVT achieves high rates of large-vessel reperfusion, clinical outcomes are significantly influenced by underlying comorbidities. Chronic hypertension impairs collateral circulation and increases the risk of cerebral edema and mortality. Diabetes mellitus is associated with reduced functional recovery and heightened hemorrhagic risk. Atrial fibrillation often leads to larger infarcts and contributes to higher unadjusted mortality. Chronic kidney disease, particularly in patients with dialysis dependence, predicts poor neurological outcomes and increased procedural complications. Active malignancy substantially elevates mortality, especially in patients with metastatic disease. Systemic comorbidities are important modifiers of outcome after EVT. While technical success rates routinely exceed 80-90%, functional recovery and survival vary significantly across patient subgroups. Meta-analyses and registry data highlight that comorbidities independently increase the risk of futile recanalization, complications, and mortality. EVT remains appropriate for medically complex patients, but optimal results require comorbidity-informed risk stratification and multidisciplinary, goal-concordant care.
Indexed as
Identifiers
40442497What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.